Neuroprotective effects of oral consumption of Bifidobacterium lactis and Lactobacillus acidophilus probiotics on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropytide-induced Parkinson’s Disease mouse model
Objective: To explore the effects of probiotics strains Bifidobacterium animalis subsp. lactis (B.lactis) and Lactobacillus acidophilus (L.acidophilus) on the inflammation of gut-brain axis and degeneration…Novel modifiers of heterozygous pathogenic Parkin variant penetrance in Parkinson’s disease
Objective: To identify novel genes and pathways acting as modifiers of pathogenic Parkin variant (PV) penetrance in affected compared to unaffected carriers of heterozygous Parkin PVs…Parkinsonism in sjogren disease
Objective: explain the cause of parkinsonism in Sjogren's syndrome Background: Sjogren's syndrome (SS) may be associated with various pathologies of the central nervous system. It…COPS: Continuous Observation of Parkinsonian Symptoms – A prospective data acquisition study using wearable accelerometery
Objective: To investigate the continuous and objective assessment of motor symptom severity in Parkinson’s Disease (PD) in everyday life. Background: Treatment adjustments in PD patients…Sympathetic tone abnormalities in subjects at risk for Parkinson’s Disease without evidence of nigrostriatal neurodegeneration: a multimodal biomarker study
Objective: To study autonomic dysfunction in subjects with idiopathic REM sleep behavior disorder (iRBD) and at least one pre-motor symptom of Parkinson's disease (PD). Background:…Safety in Levodopa/carbidopa Intestinal Gel (LCGI) titration in the Intensive Care Unit (ICU) setting for Parkinson’s Disease (PD) patient with severe dysphagia
Objective: Describe a PD patient with obsessive-compulsive disorder (OCD) and paranoid symptoms in whom treatment with LCIG was started in the ICU due to severe…Data-driven subtypes of multiple system atrophy and the implication on prognosis
Objective: To determine the clinical subtypes of MSA using data-driven approach and to compare the differences of the subtypes on survival and bed-ridden rates. Background:…SYNCHRONIZE: Real-world retrospective safety analysis in patients treated with onabotulinumtoxinA for more than one therapeutic indication
Objective: Report real-world safety of onabotulinumtoxinA used concomitantly for multiple therapeutic indications. Background: Therapeutic onabotulinumtoxinA is approved in the US for 12 indications, some of…Patient characteristics and real-world use of botulinum toxins for treatment of cervical dystonia and blepharospasm
Objective: To describe the characteristics of patients with cervical dystonia (CD) or blepharospasm (BLEPH) treated with botulinum toxin (BoNT) in routine care using claims data…Clinical severity in Parkinson’s disease is determined by decline in cortical compensation
Objective: We tested whether inter- and intra-individual differences in clinical severity are determined by cortical compensation, and not just by basal ganglia dysfunction. Background: Motor…
- « Previous Page
- 1
- …
- 281
- 282
- 283
- 284
- 285
- …
- 1554
- Next Page »